Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipid…

HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia

Estimated

~$10 – $8,750

Verve Therapeutics, Inc.NCT06451770